Kilitch Drugs carries a seven-year run of unqualified audit opinions and a clean regulatory record, but three things sit outside that frame: a ₹61 crore foreign subsidiary has gone unaudited for six years while its losses deepened, customer payments have stretched to 186 days, and the statutory auditor resigned mid-tenure in 2024.
Key findings
- The statutory auditor resigned mid-tenure in August 2024 after less than three years of a five-year term
Major- M/s Suryaprakash Maurya & Co. was appointed in September 2021 for a five-year term ending in 2026 but resigned effective 13 August 2024, citing pre-occupation and the need for a larger team. The outgoing auditor stated "Any other facts relevant to the resignation: None". M/s C. Sharat & Associates was appointed for a truncated three-year term ending in 2027, and confirmed the outgoing auditor raised no issues, objections or concerns. - Three generations of the Mehta family hold all executive director roles and control the board
Minor- The three executive directors as of 31 March 2026, Mukund Mehta (MD), Mira Mehta (MD), and Bhavin Mehta (WTD), are a single family unit. Promoter shareholding fell from 69.23% to 63.77% in FY26, a decline of 5.46 percentage points, partly driven by an inter-se gift of 8,41,046 shares from Bhavin Mehta to Mira Mehta on 23 August 2024. The company's ESOS 2007 and ESOS 2020 schemes carry an exercise price of ₹10 per share, equal to the face value. - A single procedural fine for late board-meeting intimation is the only regulatory action across seven years
Clean- In FY2025-26, BSE and NSE imposed fines for failing to furnish prior intimation for a board meeting scheduled in July 2025; the fines were paid on 26 August 2025. For each of the five fiscal years from FY2020-21 through FY2024-25, the company's Corporate Governance Reports state that no penalty or strictures were imposed by stock exchanges, SEBI, or any other statutory authority on capital market matters. As of 12 July 2025, the company confirmed that neither the company, its promoters, nor its whole-time directors had received any show-cause notices or faced prosecution proceedings from SEBI.
What to watch
- Khopoli greenfield project. Validation was expected to start "May 25" and production "another 3 months" thereafter per the Q4 FY24 transcript.
- Ethiopian government tender. A USD 9.13 million tender was disclosed in the Q4 FY24 transcript, with execution stated to begin from Q2 FY25 and payment within seven days of delivery.
- PLI vote at AGM. Shareholder vote on Performance-Linked Incentive for executive directors at the AGM on 27 August 2026.
- Disappeared income tax dispute. The ₹5.04 crore income tax dispute for A.Y. 2008-09, last reported in the FY2020-21 Annual Report, has not been disclosed since.
- Supreme Court tax matters. The Property Tax (₹53.20 lakhs) and CESS (₹22.85 lakhs) matters remain pending in the Supreme Court as of the FY2025-26 Annual Report.
Bottom line: This is a disclosed record with clean audit opinions and a near-spotless regulatory history. The weight sits in three places: an unaudited foreign subsidiary whose assets and losses have both grown, receivables that have stretched to 186 days alongside a shifting disclosure on customer concentration, and an auditor resignation mid-tenure. Watch whether the Ethiopian subsidiary gets audited and whether the USD 9.13 million tender converts to cash.